Why are there different types of MG?

The different types are defined by the specific protein targeted by the autoantibodies. The most common is acetylcholine receptor (AChR) MG, but others include MuSK-MG and LRP4-MG. Each type has a unique underlying mechanism of damage.

How do your cell models mimic these different types?

We use specific cell lines engineered to express the relevant targets (AChR, MuSK, LRP4) and associated proteins. We then apply subtype-specific stimuli and autoantibodies (e.g., complement-fixing IgG1 for AChR-MG, inhibitory IgG4 for MuSK-MG) to recreate the distinct pathologies.

Can I test my own therapeutic antibody?

Yes. Our platforms are ideal for testing the efficacy of proprietary therapeutic antibodies, fragments, or other biologics.

Are these models suitable for screening small molecule drugs?

Yes, they are well-suited for screening small molecules designed to protect the NMJ, enhance signaling pathways, or inhibit downstream damaging processes.

How do I get started?

Simply contact us through the form below or email our business development team. We will schedule a confidential discussion with one of our MG specialists to define your project needs and provide a detailed proposal.

Online Inquiry

Myasthenia Gravis Cell Model Products

Introduction Types Advantages Applications FAQs Related Product Sections Product List

Introduction

Myasthenia Gravis (MG) manifests as an intricate autoimmune channelopathy, its debilitating effects originating from a strikingly heterogeneous pathogenesis targeting the neuromuscular junction (NMJ). The sheer diversity of autoantigenic targets—encompassing not only the canonical acetylcholine receptor (AChR) but also muscle-specific kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4)—along with the divergent immunological cascades they trigger, presents profound impediments to unifying drug discovery efforts. Progress fundamentally requires sophisticated preclinical models. To successfully engineer next-generation therapies, these systems must exhibit high physiological fidelity, accurately recapitulating the complex human disease state in vitro.

Addressing this critical research exigency, Creative Biolabs offers a portfolio of advanced Myasthenia Gravis cell model products and associated services. Leveraging precise bioengineering and a nuanced understanding of MG immunopathology, we provide investigators with robust, validated tools. These models are engineered to de-risk research programs, elevate the quality and predictive power of preclinical data, and ultimately accelerate the entire therapeutic development pipeline from initial discovery toward clinical validation. Contact our experts to accelerate your MG research. Partner with us to design a study that answers your most critical questions.

For a detailed enumeration of our specific offerings, please consult our comprehensive Product List.

Types of Myasthenia Gravis Models

Creative Biolabs provides an extensive range of off-the-shelf and custom-developed cell models to suit your specific research objectives.

Types	Description
Specialized and Genetically Engineered Cell Lines	We provide a range of industry-standard muscle-like cell lines, ideal for in vitro studies of postsynaptic mechanisms and high-throughput screening. These can be custom-engineered to overexpress or knock down key NMJ proteins (e.g., MuSK, LRP4, Dok7) to investigate specific signaling pathways.
Primary Human and Murine Cell Cultures	The available models encompass proprietary Preconditioned Mesenchymal Stem Cells (cMSCs) exhibiting a demonstrably potentiated immunomodulatory capacity, alongside Thymic Epithelial Cells (TECs) for the mechanistic interrogation of intrathymic autoantigen presentation. This offering is further complemented by a comprehensive suite of primary immune cells—including PBMCs, B-cells, and T-cells—procured from both Myasthenia Gravis patient cohorts and healthy, matched control donors.
Custom Cell Model Development	Partner with our experts to develop bespoke in vitro systems. We can create advanced co-culture models tailored to reflect distinct MG subtypes (AChR, MuSK, LRP4) or cell-based assays that utilize specific TLR agonists (Poly(I:C), LPS) to mimic the inflammatory triggers of autoimmunity.

Advantages

A core strategic imperative in therapeutic development is the systematic mitigation of risk across the preclinical-to-clinical translational pipeline. Engagement with the specialized platforms offered by Creative Biolabs provides investigators with a critical asset for navigating this complex and highly competitive research landscape.

Unravel Complex Mechanisms

Our models are designed to dissect the fundamentally different pathogenic pathways of AChR vs. MuSK autoantibodies, providing clarity for your mechanism-of-action studies.

Increase Predictive Power

By accurately mimicking the in vivo pathology, our cell-based assays offer higher predictive validity for clinical success compared to conventional methods.

Accelerate Your Pipeline

Generate decisive data quickly to support lead optimization, candidate selection, and IND-enabling studies.

Access World-Class Expertise

Our team isn't just a service provider; we are your scientific partners, offering deep expertise in neuromuscular and autoimmune diseases to help you interpret results and plan your next steps.

Applications

Our Myasthenia Gravis cell models are a powerful tool for a wide range of discovery and preclinical applications.

Applications	Description
Therapeutic Efficacy Screening	Evaluate the ability of monoclonal antibodies, small molecules, or other biologics to prevent NMJ damage and restore function.
Mechanism of Action (MoA) Studies	Elucidate precisely how your therapeutic candidate works, whether by inhibiting complement, modulating signaling pathways, or protecting AChR clusters.
Investigating Seronegative MG	Test patient samples or novel antibodies on our clustered AChR and LRP4 models to identify previously undetectable pathogenic autoantibodies.
Drug & Antibody Isotype Characterization	Directly compare the pathogenic potential of different antibody isotypes (e.g., IgG1 vs. IgG4) and their susceptibility to therapeutic intervention.
Target Validation	Confirm the role of novel molecular targets in the pathogenesis of MG.

A picture that presents Mechanistic hypothesis. (Ma, et al., 2024) (OA Literature)

Fig.1 Mechanistic hypothesis of acetylcholine receptor (AChR) myasthenia gravis (MG) autoantibody production and pathogenesis of AChR antibodies.¹

FAQs

Why are there different types of MG?
The different types are defined by the specific protein targeted by the autoantibodies. The most common is acetylcholine receptor (AChR) MG, but others include MuSK-MG and LRP4-MG. Each type has a unique underlying mechanism of damage.
How do your cell models mimic these different types?
We use specific cell lines engineered to express the relevant targets (AChR, MuSK, LRP4) and associated proteins. We then apply subtype-specific stimuli and autoantibodies (e.g., complement-fixing IgG1 for AChR-MG, inhibitory IgG4 for MuSK-MG) to recreate the distinct pathologies.
Can I test my own therapeutic antibody?
Yes. Our platforms are ideal for testing the efficacy of proprietary therapeutic antibodies, fragments, or other biologics.
Are these models suitable for screening small molecule drugs?
Yes, they are well-suited for screening small molecules designed to protect the NMJ, enhance signaling pathways, or inhibit downstream damaging processes.
How do I get started?
Simply contact us through the form below or email our business development team. We will schedule a confidential discussion with one of our MG specialists to define your project needs and provide a detailed proposal.

The complexity of Myasthenia Gravis demands more than just a standard assay. It requires a deep understanding of the distinct pathologies that drive the disease. By synergistically integrating advanced cellular engineering with deep expertise in neuromuscular pathophysiology, we have developed highly specialized in vitro platforms. These systems are precisely engineered to elucidate complex disease mechanisms, thereby providing the robust empirical foundation required to accelerate the discovery and development of novel therapeutic modalities.

Let's discuss how our tailored MG cell models can advance your research program. Contact our team today for a confidential consultation and a customized quote.